Hemp Research — Page 157

Peer-reviewed industrial hemp research papers, sorted by publication date. Browse the latest findings on hemp cultivation, processing, materials science, biomedical applications, and regulatory science from PubMed, OpenAlex, and other indexed sources.

The Legalization of Medical Marijuana: A Human Rights Law Perspective (2022)

The discourse on legalizing marijuana for medical purposes in Indonesia peaked when legislators discussed the draft law on the narcotics law amendment. Efforts to legalize marijuana for medical purposes have also been pursued by testing the narcotics law. However, through decision number 106/PUU-XVII/2020, the Constitutional Court prohibited medical marijuana as a medical treatment. From the Human Rights perspective, everyone has the right to life and health. Therefore, in society's logic, the p

Capturing seizures in clinical trials of antiseizure medications for KCNQ2‐DEE (2021)

Literature review of patients with <i>KCNQ2</i> developmental and epileptic encephalopathy (<i>KCNQ2</i>-DEE) reveals, based on 16 reports including 139 patients, a clinical phenotype that includes age- and disease-specific stereotyped seizures. The typical seizure type of <i>KCNQ2</i>-DEE, focal tonic, starts within 0-5 days of life and is readily captured by video-electroencephalography VEEG for clinical and genetic diagnosis. After initial identification, <i>KCNQ2</i>-DEE seizures are clinica

Seizure and movement disorder in CACNA1E developmental and epileptic encephalopathy: Two sides of the same coin or same side of two different coins? (2024)

Pathogenic variants in CACNA1E are associated with early-onset epileptic and developmental encephalopathy (DEE). Severe to profound global developmental delay, early-onset refractory seizures, severe hypotonia, and macrocephaly are the main clinical features. Patients harboring the recurrent CACNA1E variant p.(Gly352Arg) typically present with the combination of early-onset DEE, dystonia/dyskinesia, and contractures. We describe a 2-year-and-11-month-old girl carrying the p.(Gly352Arg) CACNA1E v

Epilepsy and other comorbidities in Down syndrome (2022)

Abstract Down syndrome (DS) is the most common cause of intellectual disability. Due to many genetic and biochemical aberrations, people with DS suffer from several somatic disorders and concomitant diseases. Epilepsies occur more often than in the normal population, but less often than with intellectual disability of other causes. Epilepsies in DS have a trimodal distribution with age-related phenotypes, etiologies, and prognosis. The most common epilepsy syndrome in infancy is the often-self-l

Epilepsy in cardiofaciocutaneous syndrome: Clinical burden and response to anti‐seizure medication (2023)

Treatment-resistant epilepsy is among the most serious complications of cardiofaciocutaneous syndrome (CFCS), a rare disorder caused by germline variants in the RAS-MAPK signaling pathway. This study analyzed the clinical characteristics of epilepsy and response to anti-seizure medications (ASMs) in a multinational CFCS cohort. A caregiver survey provided data regarding seizure history, use of ASMs and other treatment approaches, adverse effects, caregiver perception of treatment response, and n

Brain temperature, brain metabolites, and immune system phenotypes in temporal lobe epilepsy (2024)

Neuroinflammation is associated with excessive heat production which can be visualized with magnetic resonance spectroscopic imaging and thermometry (MRSI-t). We prospectively investigated the relationship between MRSI-t and cellular and serum measures of peripheral inflammation in patients with temporal lobe epilepsy (TLE); we compared the results of MRSI-t in patients with TLE to healthy controls. We showed a relationship between the temperature elevations in TLE and elevations of various meas

Anticonvulsants: The Psychotropic and Medically Protective Drugs of the Future (2021)

After more than a century of scientific study and philosophical debate, the neurobiology of psychiatric disorders is still unclear. However, an emerging hypothesis contends that psychiatric and related functional symptoms are rooted in an inherent hyperexcitability of the neurological system. Particularly under the influence of stress, too many neurons fire for too long, resulting in circuit-specific psychiatric symptoms such as anxiety, depression, irritability, insomnia, inattention, and obses

Revisão Bibliográfica Sistematica - Sistema de Endocanabinoides Tendências de Uso na Farmacologia (2020)

A maconha é uma planta utilizada desde a Antiguidade com finalidade medicinal, atuando clinicamente como sedativo, analgésico e antiemético. O principal efeito colateral é a perturbação do sistema nervoso central, causando euforia e alucinações, levando a movimentação popular em favor da proibição, apesar de ser menos viciante e perigoso que etanol e derivados opioides. Em 1964, foi isolado o ?9-tetrahidrocanabinol, principal psicoativo da maconha, levando a hipótese de que seu mecanismo de ação

A Comprehensive Review of Fragile X Syndrome and Fragile X Premutation Associated Conditions in Africa (2024)

Fragile X syndrome (FXS) is a genetic disorder caused by a mutation in the fragile X messenger ribonucleoprotein 1 (<i>FMR1</i>) gene and known to be a leading cause of inherited intellectual disability globally. It results in a range of intellectual, developmental, and behavioral problems. Fragile X premutation-associated conditions (FXPAC), caused by a smaller CGG expansion (55 to 200 CGG repeats) in the <i>FMR1</i> gene, are linked to other conditions that increase morbidity and mortality for

Scoping review of disease-modifying effect of drugs in experimental epilepsy (2023)

Our review highlights the need for consistent methodology in epilepsy research and provides a novel approach for future research. Inconsistent experimental designs hinder study comparison, slowing the progression of treatments for epilepsy. If the research community can optimize and standardize parameters such as methods of seizure induction, administration schedule, sampling time, and aniMal models, more robust meta-analysis and collaborative research would follow. Additionally, some compounds

Investigation of Anticonvulsant Potential of Morus alba, Angelica archangelica, Valeriana officinalis, and Passiflora incarnata Extracts: In Vivo and In Silico Studies (2025)

The current study evaluated the anticonvulsant properties of ethanolic extracts from <i>Morus alba, Angelica archangelica</i>, <i>Passiflora incarnata</i>, and <i>Valeriana officinalis</i> using integrated phytochemical, in vivo, biochemical, and computational approaches. Phytochemical analysis by UHPLC-HRMS/MS revealed the presence of various bioactive compounds, notably flavonoids such as isorhamnetin, quercetin, and kaempferol. In an electroshock-induced seizure model, <i>Morus alba</i> extra

Carvedilol increases seizure resistance in a mouse model of SCN8A-derived epilepsy (2024)

Patients with mutations that alter the function of the sodium channel <i>SCN8A</i> present with a range of clinical features, including mild to severe seizures, developmental delay, intellectual disability, autism, feeding dysfunction, motor impairment, and hypotonia. In an effort to identify compounds that could be potentially beneficial in <i>SCN8A-</i>associated epilepsy, Atkin et al. conducted an <i>in vitro</i> screen which resulted in the identification of 90 compounds that effectively red

Development of an Antiseizure Drug Screening Platform for Dravet Syndrome at the NINDS contract site for the Epilepsy Therapy Screening Program (2020)

Summary Objective Dravet syndrome (DS) is a rare, but catastrophic genetic epilepsy, with 80% of patients with carrying a mutation in the SCN1A gene. Currently, no anti-seizure drug (ASD) exists that adequately controls seizures. Patients with DS often present clinically with a febrile seizure and generalized tonic-clonic seizures that continue throughout life. To facilitate the development of ASDs for DS, the contract site of the NINDS Epilepsy Therapy Screening Program (ETSP) has evaluated a m

Cannabis in primary care (2019)

The reclassifying of cannabis to a schedule 2 drug in November 2018 was seen as a landmark moment for patients, indicating a shift in medical policy, and more importantly, attitude toward medicinal cannabis within the UK. Following a change in legislation and subsequent guidance from the Royal College of Physicians and the British Paediatric Neurology Association, the RCGP issued its own desktop guidance for GPs to enable informed discussions with patients around this subject matter.1 Draft Nati

Switching from zonisamide to perampanel improved the frequency of seizures caused by hyperthermia in Dravet syndrome: a case report (2024)

Dravet syndrome usually begins with generalized clonic seizures in its infancy because of fever and progresses to various seizure types, often triggered by fever or seizure-induced heat due to mutations in the SCN1A gene that increases neuronal excitability. Seizures usually diminish with age, but the heat sensitivity remains. In this case, seizures were increased by repeated infections, and hyperthermia was induced by zonisamide, resulting in status epilepticus. Perampanel, an aminomethylphosph